EUVIMEDEUVIMED entdecken
Übersichtsarbeit

SOHO State of the Art Updates and Next Questions | Peripheral T-Cell Lymphoma: Current Landscape and Emerging Questions

Seda S Tolu, Barbara Pro

Clinical Lymphoma Myeloma and Leukemia · 2026-06 · 26 (6) · 341-350

DOI: 10.1016/j.clml.2026.02.007 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-06. Verfasst von Seda S Tolu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Columbia University Irving Medical Center, New York, NY. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Peripheral. Die Arbeit nennt 124 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peripheral T-cell lymphomas (PTCLs) comprise a rare, heterogeneous group of mature T-cell and NK-cell neoplasms, representing approximately 10% to 15% of all non-Hodgkin lymphomas. Despite advances in disease classification and biology, clinical outcomes remain poor for most subtypes other than anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). This review synthesizes current understanding of nodal PTCL biology-including T-cell follicular helper (TFH)-derived lymphomas, PTCL-NOS, and systemic ALCL. The integration of molecular profiling has deepened our understanding of disease heterogeneity, identifying recurrent epigenetic and signaling pathway alterations that now inform rational, targeted strategies. Brentuximab vedotin-based regimens have reshaped frontline therapy for CD30-positive disease, while ongoing studies are exploring the role of novel therapies including epigenetic modulators, phosphatidylinositol 3-kinase (PI3K) and JAK inhibitors, and immune-based therapies across the PTCL spectrum. Future progress will depend on biomarker-driven clinical trials, refined patient selection, and the incorporation of genomic and immune signatures to personalize therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, PeripheralHumansBiomarkers, TumorEpigenesis, Genetic

Stichwörter der Autor:innen

Biomarker-driven clinical trialsEpigenetic dysregulationMolecular profilingTargeted and immune-based therapies

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medicine, Columbia University Irving Medical Center, New York, NY.
  • Department of Medicine, Columbia University Irving Medical Center, New York, NY. Electronic address: bp2655@cumc.columbia.edu.

Zitieren

APA

Tolu, S. S., & Pro, B. (2026). SOHO State of the Art Updates and Next Questions | Peripheral T-Cell Lymphoma: Current Landscape and Emerging Questions. Clinical Lymphoma Myeloma and Leukemia, 26(6), 341-350. https://doi.org/10.1016/j.clml.2026.02.007

Vancouver

Tolu SS, Pro B. SOHO State of the Art Updates and Next Questions | Peripheral T-Cell Lymphoma: Current Landscape and Emerging Questions. Clinical Lymphoma Myeloma and Leukemia. 2026;26(6):341-350. doi:10.1016/j.clml.2026.02.007

BibTeX
@article{Tolu2026,
  author = {Tolu, Seda S and Pro, Barbara},
  title = {SOHO State of the Art Updates and Next Questions | Peripheral T-Cell Lymphoma: Current Landscape and Emerging Questions},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {6},
  pages = {341--350},
  doi = {10.1016/j.clml.2026.02.007}
}
Kostenlos starten →